Time to surgery after completion of neoadjuvant chemotherapy does not negatively impact recurrence and survival outcomes in breast cancer patients.
Schin BekRehena SultanaSherry De Xuan DuQing Ting TanPublished in: World journal of surgery (2024)
Time to surgery after completion of neoadjuvant chemotherapy did not appear to affect recurrence or survival outcomes. Findings from this study may allow more flexibility and reduce the burden of scheduling patients for surgery within the usual four-to-eight-week window in centers with resource and scheduling constraints.
Keyphrases
- neoadjuvant chemotherapy
- minimally invasive
- coronary artery bypass
- locally advanced
- lymph node
- sentinel lymph node
- end stage renal disease
- surgical site infection
- newly diagnosed
- ejection fraction
- rectal cancer
- prognostic factors
- squamous cell carcinoma
- peritoneal dialysis
- early stage
- atrial fibrillation
- percutaneous coronary intervention
- patient reported